Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655573 · ClinicalTrials.gov registry record
A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer
A clinical trial, sponsored by Duke University.
- Terminated
- Registry status
- 7
- Enrollment target
NCT04655573 is a clinical trial that was terminated before completion, run by Duke University. The registered enrollment target is 7 participants.
The verdict
NCT04655573 was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility of generating patient derived micro-organospheres (PDMO) from patients with advanced breast cancer to determine sensitivity to the most common forms of chemotherapy used in advanced breast cancer care.
Interventions
- PROCEDURE Breast Cancer Tumor Resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-04-07 |
| Est. Completion | 2024-05-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04655573
The ClinicalTrials.gov registry entry for NCT04655573 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Breast Cancer Tumor Resection is the first listed.
NCT04655573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04655573 about?
NCT04655573 is a clinical study titled "A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer". The purpose of this study is to assess the feasibility of generating patient derived micro-organospheres (PDMO) from patients with advanced breast cancer to determine sensitivity to the most common forms of chemotherapy used in advanced breast cancer care.
What is the current status of trial NCT04655573?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2022-04-07. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT04655573?
The interventions under investigation include: Breast Cancer Tumor Resection (PROCEDURE).
Who is sponsoring clinical trial NCT04655573?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.